Boston Scientific Corporation $BSX Shares Sold by Victory Capital Management Inc.

Key Points

• Victory Capital Management trimmed its position in Boston Scientific by 38.7% in Q3, selling 305,210 shares and leaving it with 483,268 shares valued at about $47.18 million.
• CEO Michael F. Mahoney sold 160,901 shares on Feb. 2 at an average of $93.49 per share for roughly $15.04 million, reducing his stake by about 10.23%.
• The board increased the share buyback authorization to $5 billion, which supports shareholder returns, but multiple securities class-action filings have created a legal overhang that could pressure the stock.

Victory Capital Management Inc. trimmed its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 38.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 483,268 shares of the medical equipment provider's stock after selling 305,210 shares during the quarter. Victory Capital Management Inc.'s holdings in Boston Scientific were worth $47,181,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Gerber Kawasaki Wealth & Investment Management boosted its stake in shares of Boston Scientific by 3.8% during the 2nd quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,711 shares of the medical equipment provider's stock worth $291,000 after acquiring an additional 99 shares in the last quarter. Crown Wealth Group LLC boosted its position in Boston Scientific by 4.7% during the third quarter. Crown Wealth Group LLC now owns 2,238 shares of the medical equipment provider's stock worth $218,000 after acquiring an additional 100 shares during the last quarter. Sound View Wealth Advisors Group LLC boosted its stake in Boston Scientific by 3.9% during the second quarter. Sound View Wealth Advisors Group LLC now owns 2,738 shares of the medical equipment provider's stock worth $294,000 after buying an additional 103 shares during the last quarter. Cary Street Partners Investment Advisory LLC increased its stake in shares of Boston Scientific by 5.1% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 2,106 shares of the medical equipment provider's stock worth $206,000 after acquiring an additional 103 shares during the last quarter. Finally, Scotia Capital Inc. increased its position in Boston Scientific by 0.7% during the second quarter. Scotia Capital Inc. now owns 15,093 shares of the medical equipment provider's stock worth $1,621,000 after purchasing an additional 104 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have commented on BSX. The Goldman Sachs Group set a $99.00 target price on shares of Boston Scientific in a research report on Thursday, February 5th. Wall Street Zen lowered Boston Scientific from a "buy" rating to a "hold" rating in a research report on Saturday, February 7th. Mizuho reduced their target price on shares of Boston Scientific from $140.00 to $115.00 and set an "outperform" rating on the stock in a report on Thursday, February 5th. Stifel Nicolaus cut their price target on Boston Scientific from $125.00 to $110.00 and set a "buy" rating on the stock in a research note on Wednesday, February 4th. Finally, Morgan Stanley cut their price objective on shares of Boston Scientific from $130.00 to $118.00 and set an "overweight" rating on the stock in a report on Thursday, February 5th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $108.36.

Insider Buying and Selling

In other news, CEO Michael F. Mahoney sold 160,901 shares of the company's stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares of the company's stock, valued at $131,983,105.15. This represents a 10.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.50% of the company's stock.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Board increased share buyback authorization to $5 billion, which supports EPS and provides a buyback backstop that can limit downside and return capital to shareholders. Boston Scientific (BSX) Raises Share Buyback Authorization To $5B
• Positive Sentiment: Boston Scientific will host an investor event and live webcast at the American College of Cardiology meeting on March 28 to discuss clinical data — a chance for management to highlight growth drivers and reassure investors on clinical/market progress. Boston Scientific to host investor event at the 75th Annual Scientific Session of the American College of Cardiology
• Neutral Sentiment: Coverage and commentaries note BSX is about 6% lower since last earnings — analysts point to mixed cues from the earnings release (modest beat on EPS, revenue roughly in line, and guidance ranges) and market reactions to forward views; this helps explain recent selling pressure but is not new company-specific bad news. Why Is Boston Scientific (BSX) Down 6% Since Last Earnings Report?
• Negative Sentiment: A wave of securities-class-action filings and investor-alert notices from multiple law firms allege wrongdoing for purchasers between July 23, 2025 and Feb 3, 2026 — several firms (Robbins LLP, Rosen, Bernstein Liebhard, Faruqi & Faruqi, Levi & Korsinsky, Gainey McKenna & Egleston) have issued notices and reminder deadlines, creating a legal overhang that can pressure the stock and increase uncertainty/costs. BSX Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Lawsuit Rosen Law Firm Urges Boston Scientific Stockholders to Contact the Firm Bernstein Liebhard Investor Alert

Boston Scientific Price Performance

Shares of NYSE BSX opened at $71.24 on Friday. The firm has a market capitalization of $105.71 billion, a P/E ratio of 36.72, a PEG ratio of 1.00 and a beta of 0.69. Boston Scientific Corporation has a one year low of $70.75 and a one year high of $109.50. The company's fifty day moving average is $85.03 and its two-hundred day moving average is $94.55. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.78 by $0.02. The company had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.Boston Scientific's revenue was up 15.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.